Targeting<i>NRAS</i>Mutations in Advanced Melanoma
Manali S. Phadke, Keiran S.M. Smalley
Abstract
Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. March 22, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00205 Journal of Clinical Oncology - published online before print March 22, 2023 PMID: 36947724 Targeting NRAS Mutations in Advanced Melanoma Manali S. Phadke, PhD1xManali S. PhadkeSearch for articles by this author and Keiran S.M. Smalley , PhD1,2xKeiran S.M. SmalleySearch for articles by this author Show More 1Department of Tumor Biology, Moffitt Cancer Center & Research Institute, Tampa, FL2Department of Cutaneous Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL https://doi.org/10.1200/JCO.23.00205 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologySUPPORTSupported by the National Cancer Institute (R01 CA256193, R01 CA262483, R21 CA256289, R21 CA267141) and the Melanoma Research Foundation and Revolution Medicines.AUTHOR CONTRIBUTIONSConception and design: Keiran S.M. SmalleyCollection and assembly of data: Manali S. PhadkeManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTTargeting NRAS Mutations in Advanced MelanomaThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Keiran S.M. SmalleyResearch Funding: Revolution Medicines (Inst)No other potential conflicts of interest were reported. Companion Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study